DESIGN & SYNTHESIS OF HYBRID MOLECULES FOR THE TREATMENT OF TUBERCULOSIS

Abstract

Tuberculosis is highly communicable disease that has cursed humanity for many years & its resistance is a global threat, caused primarily by Mycobacterium Tuberculosis. In order to improve the efficiency of current drugs, one approach involves the use of the so called hybrid drugs, which comprises the incorporation of two drugs in a single molecule with the intention of exerting dual drug action As mycobacterium has gained resistance to the first line anti-TB drugs, the hybrids of first line anti-TB drugs may prove a better therapeutic regimen. The coupling of first line anti-TB drugs like ethambutol with various hydrazides derivatives may prove effective, in treatment of TB. As hydrazides & ethambutol are not much effective as they were before, the coupling of these may result in increase in potency, can use in multiple targets & decrease in toxicity. The synthesized hybrid AMG-3 shows good in-vitro activity with IC50 value 1.589 μg/ml. Thus, hybrids of ethambutol with various hydrazides derivatives may prove to be the effective weapon against TB & it’s may give rise to new scaffolds in treatment of TB.